Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofacitinib (Primary)
Indications COVID-19 pneumonia; Respiratory insufficiency
Focus Registrational; Therapeutic Use
Acronyms STOP-COVID19
Sponsors Pfizer

Most Recent Events

02 Aug 2021 Status changed from active, no longer recruiting to completed.
16 Jun 2021 Primary endpoint (Death or respiratory failure ate Day 28) has been met ad per Results published in the New England Journal of Medicine.
16 Jun 2021 Results assessing efficacy and safety of tofacitinib in patients with Covid-19 pneumonia, published in the New England Journal of Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com